Quantbot Technologies LP Acquires New Holdings in Esperion Therapeutics, Inc. $ESPR

Quantbot Technologies LP acquired a new position in shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 179,639 shares of the biopharmaceutical company’s stock, valued at approximately $476,000. Quantbot Technologies LP owned 0.09% of Esperion Therapeutics at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Two Seas Capital LP boosted its holdings in shares of Esperion Therapeutics by 43.6% in the second quarter. Two Seas Capital LP now owns 9,954,975 shares of the biopharmaceutical company’s stock valued at $9,800,000 after acquiring an additional 3,024,104 shares in the last quarter. AIGH Capital Management LLC acquired a new stake in Esperion Therapeutics during the 3rd quarter worth about $7,950,000. Marshall Wace LLP raised its holdings in shares of Esperion Therapeutics by 46.2% during the second quarter. Marshall Wace LLP now owns 5,312,252 shares of the biopharmaceutical company’s stock valued at $5,206,000 after acquiring an additional 1,679,294 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of Esperion Therapeutics by 68.4% in the third quarter. JPMorgan Chase & Co. now owns 945,491 shares of the biopharmaceutical company’s stock valued at $2,506,000 after purchasing an additional 384,095 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in Esperion Therapeutics by 3.2% in the 3rd quarter. Vanguard Group Inc. now owns 12,092,449 shares of the biopharmaceutical company’s stock worth $32,045,000 after acquiring an additional 375,620 shares in the last quarter. Institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Stock Performance

Esperion Therapeutics stock opened at $3.04 on Tuesday. Esperion Therapeutics, Inc. has a 52 week low of $0.69 and a 52 week high of $4.18. The business’s fifty day moving average is $3.37 and its two-hundred day moving average is $3.14. The firm has a market cap of $726.74 million, a P/E ratio of -6.08, a P/E/G ratio of 0.56 and a beta of 1.11.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Citigroup reissued a “market outperform” rating on shares of Esperion Therapeutics in a research note on Wednesday, November 12th. Piper Sandler initiated coverage on Esperion Therapeutics in a research report on Tuesday, November 25th. They set an “overweight” rating and a $9.00 target price for the company. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Esperion Therapeutics in a research report on Wednesday, November 12th. Needham & Company LLC boosted their target price on shares of Esperion Therapeutics from $4.00 to $5.00 and gave the stock a “buy” rating in a research report on Tuesday, March 3rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Esperion Therapeutics in a report on Thursday, January 22nd. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $8.25.

Insider Buying and Selling at Esperion Therapeutics

In related news, CFO Benjamin Halladay sold 7,337 shares of the firm’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $3.67, for a total value of $26,926.79. Following the completion of the sale, the chief financial officer owned 467,525 shares of the company’s stock, valued at $1,715,816.75. This trade represents a 1.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders have sold a total of 15,543 shares of company stock valued at $55,709 over the last three months. Company insiders own 1.70% of the company’s stock.

Esperion Therapeutics Profile

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.